BERLIN--(BUSINESS WIRE)--Regulatory News:
NOXXON Pharma N.V. (Paris:ALNOX) a clinical-stage biopharmaceutical company primarily focused on cancer treatment, announced that it presented data yesterday at the ESMO conference in Copenhagen, Denmark, studying the role of CXCL12 inhibition by NOX-A12 (olaptesed pegol) in tumor stroma spheroids, a preclinical model that mimics the complexity of the tumor microenvironment. These studies showed that NOX-A12 synergizes with therapies working through either T cells or NK cells. Further studies of NOX-A12 with agents working through T-cells such as checkpoint inhibitors or CAR-T cells as well as NK cell-based therapies are warranted.
Poster Title: CXCL12 Inhibition with NOX-A12 (Olaptesed Pegol)
Increases T and NK Cell Infiltration and Synergizes with Immune
Checkpoint Blockade and ADCC in Tumour-Stroma Spheroids
Authors:
Dirk Zboralski, Anna Kruschinski, Dirk Eulberg and Axel Vater
Location
& time: ESMO Congress 2016, Copenhagen, Denmark, 7-11 October
2016, Session Immunotherapy of cancer: Abstract #1083P, Hall E, Sunday,
9 October 2016, 13:00 - 14:00
The poster may be downloaded from the company’s website:
www.noxxon.com/downloads/poster/ESMO2016.pdf
NOX-A12, which inhibits the key tumor microenvironment chemokine CXCL12, may be a key partner for a wide range of IO (immuno-oncology) agents. NOXXON has generated promising pre-clinical and clinical data, including recent animal data showing synergy with a checkpoint inhibitor as well as recent phase 2a trials in multiple myeloma and a second hematological cancer that showed a safety profile that supports further development and first signs of efficacy. The company believes that additional clinical trials are warranted to investigate combinations of NOX-A12 multiple classes of IO agents including those acting on or through T-cells and NK cells.
About NOXXON
NOXXON Pharma N.V. is a clinical-stage
biopharmaceutical company focused on cancer treatment. NOXXON’s goal is
to significantly enhance the effectiveness of cancer treatments
including immuno-oncology approaches (such as immune checkpoint
inhibitors) and current standards of care (such as chemotherapy and
radiotherapy). NOXXON’s Spiegelmer® platform has
generated a proprietary pipeline of clinical-stage product candidates
including its lead cancer drug candidate NOX-A12. NOXXON is supported by
a strong group of leading international investors, including TVM
Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners,
DEWB, NGN and Seventure. NOXXON has its statutory seat in Amsterdam, The
Netherlands and its office in Berlin, Germany. Further information can
be found at: www.noxxon.com